INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. We use proprietary technology to design DNA plasmids —small circular DNA molecules that work like software that the body’s cells can download to learn how to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA® delivery devices help ensure our DNA medicines enter the body’s cells for optimal effect.
LAURENT HUMEAU, Ph.D.
Chief Scientific Officer
“Our research is advancing the next generation of DNA medicine technology and driving innovation in how we treat and protect people from disease.”
Learn More
MARK TWYMAN, MBA
Chief Commercial Officer
“Our goal is to redefine success in the treatment of HPV-related diseases, cancer and beyond, for patients across the globe. DNA medicine offers ground-breaking potential advantages.”
Learn More
STEPHEN KEMMERRER
Senior Vice President, Engineering Development
“Our cutting-edge delivery technology helps our DNA medicines get where they need to be for optimal impact – inside the cell, providing instructions to fight disease.”
Learn More
JACQUELINE SHEA, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER
"INOVIO is committed to developing innovative new medicines for patients. We are building a uniquely experienced team, with a focus on scientific and operational excellence, to bring our DNA medicine candidates to market to benefit patients."
Learn More
PETER KIES
CHIEF FINANCIAL OFFICER
“DNA medicine has the potential to be transformational for patients around the world. We are dedicated to delivering on that promise.”
Learn More
MICHAEL SUMNER
Chief Medical Officer
“Across our pipeline we’re working to advance DNA medicine and develop innovative, next-generation therapies with groundbreaking potential.”
Learn More
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2024 INOVIO Pharmaceuticals. All rights reserved.
